Pedia

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX NewsNetwork) -- Generex Biotechnology Corporation (Nasdaq:GNBT), theleader in drug delivery for metabolic diseases through the innerlining of the mouth, announced today that it will be making threeposter presentations at the 46th Annual Meeting of the EuropeanSociety of Pediatric Endocrinology in Helsinki, Finland June 27 --30, 200...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics

WARRINGTON, Pa., May 31, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announces publication of theone-year follow-up results from its SELECT and STAR Phase 3clinical trials for Surfaxin(r), in Pediatrics, the premier medicaljournal for pediatric healthcare practitioners. The long-term datafrom the SELECT and STAR trials concluded that Surfaxindemonstrated a statisti...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

AstraZeneca Focuses Research on Growing Childhood Condition WASHINGTON, May 22, 2007 /PRNewswire-FirstCall/ -- AstraZenecawill present several studies today regarding pediatric patientswith gastroesophageal reflux disease (GERD) during oral and postersessions at the annual Digestive Disease Week meeting held at theWashington Convention Center. The studies being presented further sup...

Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented asPlatform Presentation Aerosurf Utilizing Chrysalis Aerosol-Generator TechnologyDemonstrates Optimal Functional Activity WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announced that results from itspreviously completed Phase 2 clinical trial of Surfaxin(r)(lucinactant intr...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc.(Nasdaq: MEDI) today announced that seven abstracts will bepresented at the 2007 Pediatric Academic Societies' (PAS) AnnualMeeting demonstrating the company's commitment to advancing thescience of pediatric medicine. Data are from studies pertaining toMedImmune's approved and development-stage products, including bothmonoclon...

Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference

GAITHERSBURG, Md., March 21, 2007--MedImmune, Inc. (Nasdaq:MEDI) announced today that researchers will present data from threekey studies involving the nasal-spray flu vaccine FluMist(R)(Influenza Virus Vaccine Live, Intranasal) during the NationalAssociation of Pediatric Nurse Practitioners' (NAPNAP) 28th AnnualConference on Pediatric Health Care in Lake Buena Vista, Florida.Results of...

Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. announced today that it has completed its Phase IIclinical trial using faropenem medoxomil (faropenem) in pediatricpatients with acute otitis media (AOM), a common infection of themiddle ear. Initial analyses of the study results show that it metits primary objective to show that faropenem was effective ineradicat...